Jian Irish - Apr 1, 2025 Form 4 Insider Report for Metagenomi, Inc. (MGX)

Role
Title: President and Chief Operating Officer, Director
Signature
/s/ Matthew L. Wein, attorney-in-fact
Stock symbol
MGX
Transactions as of
Apr 1, 2025
Transactions value $
$0
Form type
4
Date filed
4/3/2025, 11:57 AM
Previous filing
Apr 3, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGX Common Stock Award $0 +23K +7.69% $0.00 322K Apr 1, 2025 Direct F1
holding MGX Common Stock 178K Apr 1, 2025 By Trust F2
holding MGX Common Stock 178K Apr 1, 2025 By Trust F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGX Stock Option (Right to Buy) Award $0 +140K $0.00 140K Apr 1, 2025 Common Stock 140K $1.32 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
F2 Shares held by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F3 Shares held by the Jian Irish 2023 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F4 25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Remarks:

Title: President and Chief Operating Officer